Fundraising Fox

/Companies

Talphera

NASDAQ: TLPH

San Mateo, US · Delaware corporation

Find your way into Talphera

Sign up to see every warm intro you have to Talphera

Paths you didn't know you had: your email and LinkedIn already hold routes to the Talphera team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with Google Already have an account? Log in

Talphera is a pharmaceutical company developing and commercializing therapies for medically supervised settings, with a lead candidate, Niyad (nafamostat mesylate), a regional anticoagulant for the extracorporeal circuit during renal replacement therapy. Its pipeline also includes nafamostat-based products for inflammatory and antiviral indications and ready-to-use prefilled syringes of ephedrine and phenylephrine for perioperative and acute-care use.

Biotech Healthtech Medical Devices

Founders & leadership

PP

Pamela P. Palmer

Pamela P. PalmerFounder

BP

Badri P DasuExecutive

SA

Shakil Aslam

Shakil Aslam ExecutiveShakil Aslam is a physician-scientist with background spanning drug discovery, translational research, clinical pharmacology, and toxicology, as well as prior academic experience in rare diseases and renal and fibrotic lung conditions. He is Executive Officer of Talphera, a pharmaceutical company developing therapies for medically supervised settings including regional anticoagulants and acute-care medications.

VJ

Vincent J. Angotti

Vincent J. AngottiExecutive

RA

Raffi Asadorian

Raffi AsadorianExecutive

Board

MW

Mark WanBoard director

AJ

Abhinav JainBoard director

MB

Marina BozilenkoBoard director

JB

Jill BroadfootBoard director

SJ

Stephen J. HoffmanBoard director

AA

Adrian AdamsBoard director

RA

Richard AfableBoard director

Reported raises · per SEC filings

Form D private placements

$43.7M disclosed across 6 rounds · 2022–2025

▶$17MraisedSep 2025 · 13 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Adrian AdamsDirector
Shakil AslamExecutive Officer
Abhinav JainDirector
Vincent J AngottiExecutive Officer, Director
Marina BozilenkoDirector
Raffi AsadorianExecutive Officer
Mark WanDirector
Jill BroadfootDirector
Stephen J HoffmanDirector
Badri P DasuExecutive Officer

Offering amount: $29M
Amount sold: $17M
First sale: Sep 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.9MraisedApr 2025 · 11 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Mark WanDirector
Badri P DasuExecutive Officer
Abhinav JainDirector
Shakil AslamExecutive Officer
Marina BozilenkoDirector
Vincent J AngottiExecutive Officer, Director
Jill BroadfootDirector
Stephen J HoffmanDirector
Adrian AdamsDirector
Raffi AsadorianExecutive Officer

Offering amount: $15M
Amount sold: $4.9M
Sales commissions: $1.1M
Placement agents: A.G.P./Alliance Global Partners, BTIG, LLC
First sale: Apr 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$6MraisedJan 2024 · 6 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Richard AfableDirector
Adrian AdamsDirector
Pamela P PalmerExecutive Officer, Director
Marina BozilenkoDirector
Howard B RosenDirector
Stephen J HoffmanDirector
Vincent J AngottiExecutive Officer, Director
Raffi AsadorianExecutive Officer
Badri DasuExecutive Officer
Abhinav JainDirector
Jill BroadfootDirector
Mark WanDirector

Offering amount: $6M
Amount sold: $6M
First sale: Jan 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10MraisedJul 2023 · 10 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Adrian AdamsDirector
Pamela P. PalmerDirector
Jill BroadfootDirector
Vincent J. AngottiExecutive Officer, Director
Richard AfableDirector
Marina BozilenkoDirector
Mark WanDirector
Raffi AsadorianExecutive Officer
Howard B. RosenDirector
Stephen J. HoffmanDirector

Offering amount: $10M
Amount sold: $10M
Sales commissions: $625K
Placement agents: H.C. Wainwright & Co., LLC
First sale: Jul 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$630KraisedAug 2022 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Stephen J. HoffmanDirector
Jill BroadfootDirector
Pamela P. PalmerExecutive Officer, Director
Mark WanDirector
Richard AfableDirector
Vincent J. AngottiExecutive Officer, Director
Raffi AsadorianExecutive Officer
Marina BozilenkoDirector
Howard B. RosenDirector
Badri DasuExecutive Officer
Adrian AdamsDirector

Offering amount: $630K
Amount sold: $630K
First sale: Aug 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5.2MraisedJan 2022 · 32 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Mark WanDirector
Badri DasuExecutive Officer
Howard RosenDirector
Vincent AngottiExecutive Officer, Director
Stephen HoffmanDirector
Mark EdwardsDirector
Marina BozilenkoDirector
Jill BroadfootDirector
Adrian AdamsDirector
Raffi AsadorianExecutive Officer
Pamela PalmerExecutive Officer, Director
Richard AfableDirector

Offering amount: $6M
Amount sold: $5.2M
First sale: Jan 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies working in the same space as Talphera.

In the news

Talphera stake disclosed by Rosalind Master Fund | TLPH SEC Filing - Form SCHEDULE 13G/Astocktitan.net · Aug 2026

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Marketprnewswire.com · Sep 2025

Frequently asked questions

What does Talphera do?: Talphera is a pharmaceutical company developing and commercializing therapies for medically supervised settings, with a lead candidate, Niyad (nafamostat mesylate), a regional anticoagulant for the extracorporeal circuit during renal replacement therapy. Its pipeline also includes nafamostat-based products for inflammatory and antiviral indications and ready-to-use prefilled syringes of ephedrine and phenylephrine for perioperative and acute-care use.
Who founded Talphera?: Talphera was founded by Pamela P. Palmer.
How much funding has Talphera raised?: Talphera has disclosed $43.7M raised across 6 rounds.
Where is Talphera headquartered?: Talphera is headquartered in San Mateo, US.